VG-101

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameVG-101
Drug Alias NameAnti-GD3/R24 antibodyAnti-GD3 monoclonal antibody - ViragenAnti-R24 monoclonal antibody - ViragenVG 101VG-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-GD3
TargetsGanglioside GD3
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesViragenMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesViragenMemorial Sloan Kettering Cancer Center
Active IndicationsN/A
Inactive IndicationsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A